Reply to: 'Further evidence of the benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection'

摘要

We read with interest about the recent study on the benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus (HBV) infection by Cosconea et al. [1]. We highly appreciate the authors' results achieved with a specific group of patients with HBV. The authors acknowledged that there is still a lack of data on HBV kidney recipients' long-term survival. Therefore, we would like to present our results supporting the French group results. The immunosuppressive treatment in patients with chronic HBV infection leads to the loss of immune control of viraemia, hepatitis reactivation, fibrosis progression and hepatocellular carcinoma (HCC) occurrence [2,3]. In 1999, Mathurin et al. precisely described the negative impact of HBV on the survival of untreated patients after kidney transplantation (RTx) [4].